Fatal Adenovirus Infection During Alemtuzumab (Anti-CD52 Monoclonal Antibody) Treatment of a Patient with Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Cavalli-Björkman, Nina; Ösby, E.; Lundin, Jeanette; Kalin, Mats; Österborg, Anders; Gruber, Astrid

doi:10.1385/mo:19:4:277

Cited by 33 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Opportunistic fungi, Pneumocystis carinii, Listeria monocytogenes, mycobacteria, and herpesviruses are seen in such settings [14]. The addition of monoclonal antibodies, especially alemtuzumab (anti-CD52), may further increase immunosuppression and thus the risk for infectious mortality [15]. Such a challenging spectrum of infections requires careful prophylaxis and specific therapy, along with ad hoc immunohistochemical tests to assess the availability of the molecular target and the appropriate administration of the corresponding antibody.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases

et al. 2007

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases

et al. 2007

View full text Add to dashboard Cite

“…Alemtuzumab is approved in the United States for therapy of B‐cell chronic lymphocytic leukemia, but has been used in other settings including management of other hematologic malignancies, autoimmune diseases, and organ transplantation. Reported infectious complications associated with its use include reactivation of hepatitis B (26), CMV (27), molluscum contagiosum (28), adenovirus (29), parvovirus B19 (30), and systemic Mycobacterium bovis infection (31). A study of fungal infections among pancreas recipients who received alemtuzumab identified 3 cases of cryptococcosis in 121 (2.4%) patients (32).…”

Section: Discussionmentioning

confidence: 99%

Cryptococcosis in liver and kidney transplant recipients receiving anti‐thymocyte globulin or alemtuzumab

Silveira

Husain

Kwak

et al. 2007

Transplant Infectious Dis

View full text Add to dashboard Cite

Rabbit anti-thymocyte globulin (ATG) and alemtuzumab have been used for induction or preconditioning and for the treatment of acute rejection in organ transplant recipients in many centers. Such regimens may lead to a substantial decline in the CD4 lymphocyte count to levels seen in other population groups at high risk of cryptococcosis. In view of this, we examined the impact of such therapy on the cumulative incidence of cryptococcosis among liver and kidney recipients. A total of 834 liver and 727 kidney transplants were performed during the study period. Seven hundred and eighty-one patients did not receive ATG or alemtuzumab; 646 received 1 dose of either drug, and 134 patients received 2 doses of either drug. The cumulative incidence of cryptococcosis was 0.26% (2/781) among those who did not receive ATG or alemtuzumab; 0.3% (2/646) among those who received only 1 dose, and 2.24% (3/134) among those who received 2 doses (P=0.03). There were 5 cases of cryptococcosis in liver recipients and 2 in kidney recipients. There were 3 cases of cryptococcal meningitis, 3 of pneumonia, and 1 of disseminated disease. The 2 kidney recipients had meningitis. Diagnosis occurred at a median of 255 days (range 7-517) after transplantation. The mortality rate was 14.2%. We conclude that the use of 1 dose of ATG or alemtuzumab is not associated with an increased cumulative incidence of cryptococcosis, but that those patients receiving 2 doses are at increased risk.

show abstract

“…18,21 However, infection risks may be accentuated with the use of alemtuzumab, as its use has been associated with higher rates of CMV reactivation and has been linked to severe cases of EBV and adenovirus infection. [23][24][25][26][27][28][29] However, these early studies on SAA show a potential central role for alemtuzumab, in particular for control of both acute and chronic GVHD.…”

Section: Impact Of High-resolution Typingmentioning

confidence: 99%

Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia

Meyers

Maziarz

2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Severe aplastic anemia (SAA) is a BM failure syndrome in which allo-SCT remains a highly effective curative option. Its application remains limited by donor availability and by the potential for treatment-related morbidity and mortality. The improved outcomes with unrelated transplantation are a result of the advent of molecular donor-recipient matching, generation of effective novel conditioning regimens, improvement of supportive care and expansion of the donor registry. Decision making regarding the earlier use of unrelated transplant procedures is rapidly evolving. This paper reviews critical data relevant to these treatment options and recommends early consideration of related SCT for patients with SAA who show failure of immune suppressive therapy.

show abstract

Fatal Adenovirus Infection During Alemtuzumab (Anti-CD52 Monoclonal Antibody) Treatment of a Patient with Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Cited by 33 publications

References 21 publications

Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases

Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases

Cryptococcosis in liver and kidney transplant recipients receiving anti‐thymocyte globulin or alemtuzumab

Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia

Contact Info

Product

Resources

About